218 related articles for article (PubMed ID: 17568025)
21. Erythropoietin-stimulating agents: new data yield new insights.
Zitella L
Oncology (Williston Park); 2007 Oct; 21(11 Suppl Nurse Ed):36-8. PubMed ID: 18154208
[No Abstract] [Full Text] [Related]
22. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
23. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
24. Reaction from renal associations. Renal Physicians Association.
Blaser R
Nephrol News Issues; 2007 May; 21(6):61-2, 64. PubMed ID: 17518126
[No Abstract] [Full Text] [Related]
25. Erythropoietin: the swinging pendulum.
Oster HS; Neumann D; Hoffman M; Mittelman M
Leuk Res; 2012 Aug; 36(8):939-44. PubMed ID: 22579365
[TBL] [Abstract][Full Text] [Related]
26. Erythropoietin claims monitoring policy: implications of the October 2006 update continuing.
Messana T
Nephrol Nurs J; 2006; 33(6):660-3; quiz 664-5. PubMed ID: 17219727
[TBL] [Abstract][Full Text] [Related]
27. Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietin.
McKoy JM; Tigue CC; Bennett CL
Cancer Treat Res; 2008; 140():235-51. PubMed ID: 18283779
[No Abstract] [Full Text] [Related]
28. Reimbursement for erythropoiesis-stimulating agents poses challenges.
Traynor K
Am J Health Syst Pharm; 2008 Mar; 65(5):385-6. PubMed ID: 18281727
[No Abstract] [Full Text] [Related]
29. New limits advised for anemia drugs.
Mitka M
JAMA; 2008 May; 299(17):2016. PubMed ID: 18460658
[No Abstract] [Full Text] [Related]
30. Epoetin alfa and darbepoetin alfa go head to head.
Steensma DP; Loprinzi CL
J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
[No Abstract] [Full Text] [Related]
31. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
Singh AK
J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
[No Abstract] [Full Text] [Related]
32. Cancer- and treatment-related anemia.
Rodgers GM; Cella D; Chanan-Khan A; Chesney C; Cleeland C; Coccia PF; Demetri GD; Djulbegovic B; Garst JL; Gore M; Kraut EH; Lin WC; Millenson M; Mock V; Reinke D; Rosenthal J; Sabbatini P
J Natl Compr Canc Netw; 2005 Nov; 3(6):772-89. PubMed ID: 16316613
[No Abstract] [Full Text] [Related]
33. Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan.
Nakagawa T
Ther Apher Dial; 2008 Dec; 12(6):531-2. PubMed ID: 19140854
[No Abstract] [Full Text] [Related]
34. Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.
Longfield V; Gebhart B; Hayward L
J Support Oncol; 2005; 3(6 Suppl 4):8-9. PubMed ID: 16355548
[No Abstract] [Full Text] [Related]
35. Utilizing quality of life as a factor in treatment choices for chemotherapy-induced anemia.
Koopman W; Iakiri S
J Support Oncol; 2005; 3(6 Suppl 4):20-1. PubMed ID: 16355554
[No Abstract] [Full Text] [Related]
36. A star rises, another fades.
Neumann ME
Nephrol News Issues; 2013 Jul; 27(8):8. PubMed ID: 23926618
[No Abstract] [Full Text] [Related]
37. Erythropoietins should be used according to guidelines.
Aapro MS; Birgegård G; Bokemeyer C; Cornes P; Foubert J; Gascon P; Glaspy J; Hellström-Lindberg E; Link H; Ludwig H; Osterborg A; Repetto L; Soubeyran P
Lancet Oncol; 2008 May; 9(5):412-3. PubMed ID: 18452853
[No Abstract] [Full Text] [Related]
38. Comparative studies on erythropoietic agents.
Straus D
J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S46-9. PubMed ID: 16280113
[No Abstract] [Full Text] [Related]
39. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
Besarab A; McCrea JB
ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
[No Abstract] [Full Text] [Related]
40. New pharmacoeconomic option in uremic anemia management.
Savica V; Mantovani L; Santoro D; Ricciardi B; Bellinghieri G
Clin Nephrol; 2007 Mar; 67(3):200. PubMed ID: 17390747
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
